BACKGROUND: Acral melanoma is a rare type of melanoma that affects world populations irrespective of skin color and has worse survival than other cutaneous melanomas. It has relatively few single nucleotide mutations without the UV signature of cutaneous melanomas, but instead has a genetic landscape characterized by structural rearrangements and amplifications. BRAF mutations are less common than in other cutaneous melanomas, and knowledge about alternative therapeutic targets is incomplete. METHODS: To identify alternative therapeutic targets, we performed targeted deep-sequencing on 122 acral melanomas. We confirmed the loss of the tumor suppressors p16 and NF1 by immunohistochemistry in select cases. RESULTS: In addition to BRAF (21.3%), NRAS (27.9%), and KIT (11.5%) mutations, we identified a broad array of MAPK pathway activating alterations, including fusions of BRAF (2.5%), NTRK3 (2.5%), ALK (0.8%), and PRKCA (0.8%), which can be targeted by available inhibitors. Inactivation of NF1 occurred in 18 cases (14.8%). Inactivation of the NF1 cooperating factor SPRED1 occurred in eight cases (6.6%) as an alternative mechanism of disrupting the negative regulation of RAS. Amplifications recurrently affected narrow loci containing PAK1 and GAB2 (n = 27, 22.1%), CDK4 (n = 27, 22.1%), CCND1 (n = 24, 19.7%), EP300 (n = 20, 16.4%), YAP1 (n = 15, 12.3%), MDM2 (n = 13, 10.7%), and TERT (n = 13, 10.7%) providing additional and possibly complementary therapeutic targets. Acral melanomas with BRAFV600E mutations harbored fewer genomic amplifications and were more common in patients with European ancestry. CONCLUSION: Our findings support a new, molecularly based subclassification of acral melanoma with potential therapeutic implications: BRAFV600E mutant acral melanomas with characteristics similar to nonacral melanomas that could benefit from BRAF inhibitor therapy, and non-BRAFV600E mutant acral melanomas. Acral melanomas without BRAFV600E mutations harbor a broad array of therapeutically relevant alterations. Expanded molecular profiling would increase the detection of potentially targetable alterations for this subtype of acral melanoma.
BACKGROUND:Acral melanoma is a rare type of melanoma that affects world populations irrespective of skin color and has worse survival than other cutaneous melanomas. It has relatively few single nucleotide mutations without the UV signature of cutaneous melanomas, but instead has a genetic landscape characterized by structural rearrangements and amplifications. BRAF mutations are less common than in other cutaneous melanomas, and knowledge about alternative therapeutic targets is incomplete. METHODS: To identify alternative therapeutic targets, we performed targeted deep-sequencing on 122 acral melanomas. We confirmed the loss of the tumor suppressors p16 and NF1 by immunohistochemistry in select cases. RESULTS: In addition to BRAF (21.3%), NRAS (27.9%), and KIT (11.5%) mutations, we identified a broad array of MAPK pathway activating alterations, including fusions of BRAF (2.5%), NTRK3 (2.5%), ALK (0.8%), and PRKCA (0.8%), which can be targeted by available inhibitors. Inactivation of NF1 occurred in 18 cases (14.8%). Inactivation of the NF1 cooperating factor SPRED1 occurred in eight cases (6.6%) as an alternative mechanism of disrupting the negative regulation of RAS. Amplifications recurrently affected narrow loci containing PAK1 and GAB2 (n = 27, 22.1%), CDK4 (n = 27, 22.1%), CCND1 (n = 24, 19.7%), EP300 (n = 20, 16.4%), YAP1 (n = 15, 12.3%), MDM2 (n = 13, 10.7%), and TERT (n = 13, 10.7%) providing additional and possibly complementary therapeutic targets. Acral melanomas with BRAFV600E mutations harbored fewer genomic amplifications and were more common in patients with European ancestry. CONCLUSION: Our findings support a new, molecularly based subclassification of acral melanoma with potential therapeutic implications: BRAFV600E mutant acral melanomas with characteristics similar to nonacral melanomas that could benefit from BRAF inhibitor therapy, and non-BRAFV600E mutant acral melanomas. Acral melanomas without BRAFV600E mutations harbor a broad array of therapeutically relevant alterations. Expanded molecular profiling would increase the detection of potentially targetable alterations for this subtype of acral melanoma.
Authors: Thomas Wiesner; Jie He; Roman Yelensky; Rosaura Esteve-Puig; Thomas Botton; Iwei Yeh; Doron Lipson; Geoff Otto; Kristina Brennan; Rajmohan Murali; Maria Garrido; Vincent A Miller; Jeffrey S Ross; Michael F Berger; Alyssa Sparatta; Gabriele Palmedo; Lorenzo Cerroni; Klaus J Busam; Heinz Kutzner; Maureen T Cronin; Philip J Stephens; Boris C Bastian Journal: Nat Commun Date: 2014 Impact factor: 14.919
Authors: Iwei Yeh; Meng Kian Tee; Thomas Botton; A Hunter Shain; Alyssa J Sparatta; Alexander Gagnon; Swapna S Vemula; Maria C Garrido; Kenji Nakamaru; Takeshi Isoyama; Timothy H McCalmont; Philip E LeBoit; Boris C Bastian Journal: J Pathol Date: 2016-11 Impact factor: 7.996
Authors: Danielle M Bello; Joanne F Chou; Katherine S Panageas; Mary S Brady; Daniel G Coit; Richard D Carvajal; Charlotte E Ariyan Journal: Ann Surg Oncol Date: 2013-07-10 Impact factor: 5.344
Authors: Moriah H Nissan; Christine A Pratilas; Alexis M Jones; Ricardo Ramirez; Helen Won; Cailian Liu; Shakuntala Tiwari; Li Kong; Aphrothiti J Hanrahan; Zhan Yao; Taha Merghoub; Antoni Ribas; Paul B Chapman; Rona Yaeger; Barry S Taylor; Nikolaus Schultz; Michael F Berger; Neal Rosen; David B Solit Journal: Cancer Res Date: 2014-02-27 Impact factor: 12.701
Authors: Basil Horst; Sofia K Gruvberger-Saal; Benjamin D Hopkins; Lindsey Bordone; Ying Yang; Karen A Chernoff; Ijeoma Uzoma; Volker Schwipper; Jutta Liebau; Norma J Nowak; Georg Brunner; David Owens; David L Rimm; Ramon Parsons; Julide Tok Celebi Journal: Am J Pathol Date: 2009-04 Impact factor: 4.307
Authors: Tobias Rausch; Thomas Zichner; Andreas Schlattl; Adrian M Stütz; Vladimir Benes; Jan O Korbel Journal: Bioinformatics Date: 2012-09-15 Impact factor: 6.937
Authors: Yian Ann Chen; Jamie K Teer; Zeynep Eroglu; Jheng-Yu Wu; John M Koomen; Florian A Karreth; Jane L Messina; Keiran S M Smalley Journal: Semin Cancer Biol Date: 2019-11-02 Impact factor: 15.707
Authors: Joshua M Weiss; Miranda V Hunter; Nelly M Cruz; Arianna Baggiolini; Mohita Tagore; Yilun Ma; Sandra Misale; Michelangelo Marasco; Theresa Simon-Vermot; Nathaniel R Campbell; Felicity Newell; James S Wilmott; Peter A Johansson; John F Thompson; Georgina V Long; John V Pearson; Graham J Mann; Richard A Scolyer; Nicola Waddell; Emily D Montal; Ting-Hsiang Huang; Philip Jonsson; Mark T A Donoghue; Christopher C Harris; Barry S Taylor; Tianhao Xu; Ronan Chaligné; Pavel V Shliaha; Ronald Hendrickson; Achim A Jungbluth; Cecilia Lezcano; Richard Koche; Lorenz Studer; Charlotte E Ariyan; David B Solit; Jedd D Wolchok; Taha Merghoub; Neal Rosen; Nicholas K Hayward; Richard M White Journal: Nature Date: 2022-03-30 Impact factor: 69.504
Authors: E Elizabeth Patton; Kristen L Mueller; David J Adams; Niroshana Anandasabapathy; Andrew E Aplin; Corine Bertolotto; Marcus Bosenberg; Craig J Ceol; Christin E Burd; Ping Chi; Meenhard Herlyn; Sheri L Holmen; Florian A Karreth; Charles K Kaufman; Shaheen Khan; Sebastian Kobold; Eleonora Leucci; Carmit Levy; David B Lombard; Amanda W Lund; Kerrie L Marie; Jean-Christophe Marine; Richard Marais; Martin McMahon; Carla Daniela Robles-Espinoza; Ze'ev A Ronai; Yardena Samuels; Maria S Soengas; Jessie Villanueva; Ashani T Weeraratna; Richard M White; Iwei Yeh; Jiyue Zhu; Leonard I Zon; Marc S Hurlbert; Glenn Merlino Journal: Cancer Cell Date: 2021-02-04 Impact factor: 31.743
Authors: Sara S Bernardes; Ingrid Ferreira; David E Elder; Aretha B Nobre; Héctor Martínez-Said; David J Adams; Carla Daniela Robles-Espinoza; Patricia A Possik Journal: J Pathol Clin Res Date: 2021-07-02
Authors: Shelly X Bian; Lindsay Hwang; Jennifer Hwang; Omar Ragab; Gino K In; David Peng; Eugene Lin Journal: Pigment Cell Melanoma Res Date: 2021-08-02 Impact factor: 4.693